Psilocybin and Medication Interactions: Evidence, Unknowns, and Safety
This page summarizes published evidence and official program safeguards. It cannot determine whether a combination is safe for a particular person. Bring a complete medication and supplement list to a qualified clinician or pharmacist.
What the evidence can—and cannot—tell us
A systematic review screened 7,102 records but found only 10 psilocybin interaction studies among 52 classic-psychedelic interaction studies. The review found attenuated effects, potentiated effects, and sometimes no measured change. Except for a small number of case reports, serious adverse drug events were not described in the included studies. That limited evidence means a missing reported interaction is not proof that a combination is safe.
Medication and substance review table
| Medication or substance | What is known | Practical safety response |
|---|---|---|
| Lithium | Case-report and survey data involving classic psychedelics include seizures. Oregon’s regulated program denies access when a client currently takes lithium or used it within the previous 30 days. | Do not combine outside qualified medical oversight. Do not stop lithium on your own. |
| SSRIs and SNRIs | Some observational data suggest reduced subjective effects during or after use; controlled data remain limited. The actual serotonin-toxicity risk with psilocybin alone is uncertain and should not be overstated. | Ask the prescriber. Never increase psilocybin exposure to “overcome” blunting, and never taper an antidepressant without a supervised plan. |
| MAOIs | Psilocin metabolism involves monoamine oxidase, so MAO inhibition may alter intensity or duration. Direct human evidence for specific combinations is limited. | Avoid unsupervised combination and obtain specialist review. |
| Antipsychotics | Some antipsychotics block serotonin receptors involved in psychedelic effects and may blunt them. The underlying condition for which the drug is prescribed can be the larger safety concern. | Do not skip medication. A history of psychosis or mania requires specialist assessment. |
| Benzodiazepines | They may reduce psychedelic effects and are sometimes used clinically for severe agitation, but evidence does not support self-directed use as a routine “trip killer.” | Use only as prescribed; do not create a home rescue protocol from online advice. |
| Stimulants and cardiovascular drugs | Psilocybin can acutely increase heart rate or blood pressure, while stimulants may add cardiovascular and anxiety effects. Evidence for individual combinations is incomplete. | Obtain prescriber review, especially with heart disease, hypertension, arrhythmia, or multiple medications. |
| Tramadol and other serotonergic drugs | Tramadol affects serotonin and has its own seizure risk. Data with psilocybin are sparse. | Avoid self-experimentation; request medication-specific guidance. |
| Alcohol, cannabis, and other psychoactive substances | Combined effects can impair judgment, intensify anxiety, or make the experience less predictable. Product identity may also be uncertain. | Avoid mixing substances, particularly without screening and supervision. |
Conditions that need additional caution
Controlled clinical studies commonly screen participants for psychotic disorders, bipolar-spectrum risk, serious cardiovascular disease, pregnancy, and other conditions that could increase risk. Oregon’s regulated program includes preparation, informed consent, safety planning, transportation planning, and facilitator review; access can be denied or referred for clinical evaluation based on medications or diagnosis.
A commercial product page cannot reproduce that screening. If you have a personal or family history of psychosis or mania, significant heart disease, uncontrolled blood pressure, pregnancy or breastfeeding, seizure history, or a complex medication regimen, seek qualified medical advice rather than relying on a generalized interaction chart.
Why “washout period” advice is not provided here
Medication half-lives, withdrawal risks, relapse risks, and interaction evidence vary. A fixed online instruction such as “stop for two weeks” can be unsafe. Any taper or washout decision belongs to the prescriber and the patient. The safer question is not “How quickly can I stop?” but “What are the risks of changing a treatment that is currently managing my condition?”
When to seek urgent help
Seek emergency care for seizure, loss of consciousness, chest pain, very high temperature, severe agitation, marked confusion, rigid muscles, difficulty breathing, or behavior that creates an immediate risk of harm. Tell clinicians what substances and medications were taken; accurate information helps them treat the problem.
Before considering any product
- Write down every prescription, over-the-counter drug, supplement, and substance used recently.
- Ask the prescriber or pharmacist about the specific combination and the risk of changing current medication.
- Verify product identity; an undisclosed ingredient makes an interaction review unreliable.
- Review the gummy label and testing checklist and the online-purchase safety checklist.
Compare the current Shrooomz product formats
Review the label information, serving format, quantity, price, and support included with each product before deciding.
View the Shrooomz Store →Frequently asked questions
Can I stop an antidepressant before using psilocybin?
Do not stop or taper it on your own. Withdrawal and symptom relapse can be serious, and interaction evidence does not establish one universal washout period.
Is lithium the highest-concern medication?
Lithium has one of the clearest serious warning signals with classic psychedelics because seizures have been reported. Oregon’s regulated program also excludes current or recent lithium use.
Do SSRIs make psilocybin dangerous?
Evidence is limited and does not support one universal answer. Some data suggest blunted subjective effects. The appropriate response is prescriber review—not increasing the psychedelic amount or stopping the SSRI independently.
Does the absence of a listed interaction mean a combination is safe?
No. The human literature is small, and many medication classes and combinations have not been adequately studied.
Sources
- Halman et al.: Drug–drug interactions involving classic psychedelics — systematic review
- Meshkat et al.: Pharmacokinetics of Psilocybin — systematic review
- Oregon Health Authority: What to know about Oregon’s psilocybin services
- Therapeutic use of psilocybin: Practical considerations for dosing and administration